{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-061155","form_type":"8-K","ticker":"COO","cik":"0000711404","company_name":"COOPER COMPANIES, INC.","filed_at":"2026-09-09T20:34:31+00:00","discovered_at":"2026-09-09T20:35:00.873865+00:00","generated_at":"2026-09-09T20:35:09.577699+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CooperCompanies Q3 EPS $2.24 GAAP, $1.15 non-GAAP; completes strategic review, buyback to $3B","bullets":["Revenue $1.066B, +1% YoY; GAAP EPS $2.24 (incl. $307.2M tax benefit), non-GAAP EPS $1.15 (+4%).","Free cash flow $273M, +66% YoY; repurchased $339.1M of stock in Q3.","Strategic review complete: Board unanimously retains CooperSurgical; buyback authorization raised from $2B to $3B.","FY2026 guidance: revenue $4.229-4.252B, non-GAAP EPS $4.51-4.55; Q4 revenue $1.057-1.080B, non-GAAP EPS $1.05-1.09.","CooperVision revenue flat at $717M; CooperSurgical revenue $349.2M, +2% (organic +3%)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-061155","json":"https://secwatch.observer/filing/0001628280-26-061155.json","markdown":"https://secwatch.observer/filing/0001628280-26-061155.md","text":"https://secwatch.observer/filing/0001628280-26-061155.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/711404/000162828026061155/0001628280-26-061155-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/711404/000162828026061155/coo-20260909.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-09T20:35:09.577699+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}